Overview

* FibroGen ( FGEN ) Q3 net income $200.6 mln, driven by sale of China operations

* Revenue from continuing operations in Q3 was $1.1 mln, up from $0.1 mln in Q3 2024

* Company expects cash to fund operations into 2028

Outlook

* FibroGen ( FGEN ) expects cash resources to fund operations into 2028

* Interim results from FG-3246 trial expected in second half of 2026

* FibroGen ( FGEN ) to submit Phase 3 roxadustat protocol in 4Q 2025

Result Drivers

* CHINA OPERATIONS SALE - Sale of FibroGen China to AstraZeneca for $220 mln simplified capital structure and extended cash runway

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net $200.64

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for FibroGen Inc ( FGEN ) is $43.00, about 74.3% above its November 7 closing price of $11.03

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)